# Efficacy and Safety of BG00012 in MS

> **NCT00168701** · PHASE2 · COMPLETED · sponsor: **Biogen** · enrollment: 260 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** BG00012

## Key facts

- **NCT ID:** NCT00168701
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-10-01
- **Primary completion:** 2006-03-31
- **Final completion:** 2006-03-31
- **Target enrollment:** 260 (ACTUAL)
- **Last updated:** 2023-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00168701

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00168701, "Efficacy and Safety of BG00012 in MS". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT00168701. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*